Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Liquid biopsy in breast cancer
SummaryCurrently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant applications in BC and give a  brief overview of potential future uses. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 23, 2024 Category: Cancer & Oncology Source Type: research

Alternating chemotherapy with VDC-IE as effective first-line treatment in a  patient with SMARCA4-deficient undifferentiated tumor
We report the case of a  43-year-old woman with thoracic SMARCA4-UT who presented with rapid progression of disease after surgical resection and achieved complete radiologic remission under VDC-IE chemotherapy (vincristine, doxorubicin, and cyclophosphamide [VDC], alternating with ifosfamide and etoposide [IE]). The detai led case report is followed by a brief discussion and overview of current literature. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

The future of clinical trials —goals, ideas, and discussion
SummaryClinical trials are subject to an ever-evolving landscape of treatment options, regulatory requirements, socioeconomic conditions, and paradigms of scientific research. In this opinion paper, we illustrate current methods and topics with a  focus on clinical trial designs, conduct and modes of collaboration. The example of successful clinical breast cancer research in Austria demonstrates the opportunities, but also the challenges for academic research. We also investigate potential pitfalls, and suggest new ideas and strategies on h ow to increase practicability along with transparency and fairness, but ultimately...
Source: Memo - Magazine of European Medical Oncology - April 18, 2024 Category: Cancer & Oncology Source Type: research

American Society of Hematology (ASH) update 2023 —chronic lymphocytic leukemia
SummaryIn recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunotherapy to the combination of targeted agents (BTK inhibitors, BCL2 inhibitors, anti-CD20 antibody), which should be administered in a time-limited manner when possible. This was also recognized in the Onkopedia Guidelines, which were recently updated [1]. At the last American Society of Hematology (ASH) meeting in San Diego (CA, USA), this trend was reflected in almost all presentations. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 18, 2024 Category: Cancer & Oncology Source Type: research

15  years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
SummaryCancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 with the aim to translate LSC concepts into clinical practice. Major specific aims of the LBI HO are to identify LSC in various blood cell disorders and to improve anti-leukemic therapies by establishing LSC-targeting and LSC-eradicating approaches with the ultimate aim to translate these concepts into clinical practice. In addition, the LBI HO identified a  number of diagnos...
Source: Memo - Magazine of European Medical Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research

Treatment-changing news in urogenital cancer —a brief unstructured narrative review based on findings presented at the ESMO 2023 conference
This article gives an overview through the most promising and practise changing studies presented for urothelial cancer at ESMO 2023 conference. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 18, 2024 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES. Report from the American Society of Hematology (ASH) Annual Meeting, December 9 –12, 2023
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 12, 2024 Category: Cancer & Oncology Source Type: research

Prediction of epidermal growth factor receptor mutation status by textural features in stage  IV lung adenocarcinoma
ConclusionsTextural features combined with clinical features could establish a  model for improving the predicting power of EGFR mutation status in patients with stage IV adenocarcinoma lung cancer. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 28, 2024 Category: Cancer & Oncology Source Type: research

Seminal vesicle metastasis from transverse colon adenocarcinoma: a  unique case report
ConclusionOur case is unique, as there are no previous reports in the literature on the relapse of metastatic colon adenocarcinoma in the seminal vesicles. Imaging with PET/CT showed compromise of the seminal vesicles in our case; hence, this imaging technique seems to have a  promising role in detecting metastatic seminal vesicle tumors. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 23, 2024 Category: Cancer & Oncology Source Type: research